These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

3970 related articles for article (PubMed ID: 6644348)

  • 1. Preliminary observations of immunomodulatory activity of lymphoblastoid interferon-alpha administered every other day or weekly.
    Neefe JR; Sullivan JE; Silgals R
    J Biol Response Mod; 1983; 2(5):441-9. PubMed ID: 6644348
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Augmentation of natural immunity and correlation with tumor response in melanoma patients treated with human lymphoblastoid interferon.
    Neefe JR; Phillips EA; Treat J
    Diagn Immunol; 1986; 4(6):299-305. PubMed ID: 3102149
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized trial of recombinant alpha 2b-interferon with or without indomethacin in patients with metastatic malignant melanoma.
    Miller RL; Steis RG; Clark JW; Smith JW; Crum E; McKnight JE; Hawkins MJ; Jones MJ; Longo DL; Urba WJ
    Cancer Res; 1989 Apr; 49(7):1871-6. PubMed ID: 2647294
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
    Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
    J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Changes in immune function in patients receiving natural leukocyte interferon.
    Maluish AE; Ortaldo JR; Sherwin SA; Oldham RK; Herberman RB
    J Biol Response Mod; 1983; 2(5):418-27. PubMed ID: 6644346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of recombinant interferon-alpha on immune function in cancer patients.
    Maluish AE; Leavitt R; Sherwin SA; Oldham RK; Herberman RB
    J Biol Response Mod; 1983; 2(5):470-81. PubMed ID: 6358423
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Augmented immunity in cancer patients treated with alpha-interferon.
    Neefe JR; Sullivan JE; Ayoob M; Phillips E; Smith FP
    Cancer Res; 1985 Feb; 45(2):874-8. PubMed ID: 3967248
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
    Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
    Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Administration of R24 monoclonal antibody and low-dose interleukin 2 for malignant melanoma.
    Soiffer RJ; Chapman PB; Murray C; Williams L; Unger P; Collins H; Houghton AN; Ritz J
    Clin Cancer Res; 1997 Jan; 3(1):17-24. PubMed ID: 9815532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase I evaluation of therapy with four schedules of 5-fluorouracil by continuous infusion combined with recombinant interferon alpha.
    Greenblatt MS; Mangalik A; Ferguson J; Elias L
    Clin Cancer Res; 1995 Jun; 1(6):615-20. PubMed ID: 9816023
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human leukocyte (alpha) interferon in metastatic malignant melanoma: the American Cancer Society phase II trial.
    Krown SE; Burk MW; Kirkwood JM; Kerr D; Morton DL; Oettgen HF
    Cancer Treat Rep; 1984 May; 68(5):723-6. PubMed ID: 6722830
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunomodulatory activities of human leukocyte interferon in advanced cancer patients.
    Bash JA; Teitelbaum D; Sreevalsan T; Neefe JR
    J Biol Response Mod; 1983; 2(1):57-65. PubMed ID: 6606019
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I trial of combined immunotherapy with subcutaneous granulocyte macrophage colony-stimulating factor, low-dose interleukin 2, and interferon alpha in progressive metastatic melanoma and renal cell carcinoma.
    de Gast GC; Klümpen HJ; Vyth-Dreese FA; Kersten MJ; Verra NC; Sein J; Batchelor D; Nooijen WJ; Schornagel JH
    Clin Cancer Res; 2000 Apr; 6(4):1267-72. PubMed ID: 10778950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Eastern cooperative group trial of interferon gamma in metastatic melanoma: an innovative study design.
    Schiller JH; Pugh M; Kirkwood JM; Karp D; Larson M; Borden E
    Clin Cancer Res; 1996 Jan; 2(1):29-36. PubMed ID: 9816086
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective randomized trial of lisofylline for the prevention of toxicities of high-dose interleukin 2 therapy in advanced renal cancer and malignant melanoma.
    Margolin K; Atkins M; Sparano J; Sosman J; Weiss G; Lotze M; Doroshow J; Mier J; O'Boyle K; Fisher R; Campbell E; Rubin J; Federighi D; Bursten S
    Clin Cancer Res; 1997 Apr; 3(4):565-72. PubMed ID: 9815721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential applications of the interferons in oncology: lessons drawn from studies of human melanoma.
    Kirkwood JM; Ernstoff M
    Semin Oncol; 1986 Sep; 13(3 Suppl 2):48-56. PubMed ID: 3532336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Depression of natural killer cytotoxicity after in vivo administration of recombinant leukocyte interferon.
    Maluish AE; Ortaldo JR; Conlon JC; Sherwin SA; Leavitt R; Strong DM; Weirnik P; Oldham RK; Herberman RB
    J Immunol; 1983 Jul; 131(1):503-7. PubMed ID: 6863923
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
    Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
    J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of in vivo administration of interferon on human monocyte function.
    Territo M; Sarna G; Figlin R
    J Biol Response Mod; 1983; 2(5):450-7. PubMed ID: 6644349
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II clinical trial of combined natural interferon-beta plus recombinant interferon-gamma treatment of chronic hepatitis B.
    Musch E; Högemann B; Gerritzen A; Fischer HP; Wiese M; Kruis W; Malek M; Gugler R; Schmidt G; Huchzermeyer H; Gerlach U; Dengler HJ; Sauerbruch T
    Hepatogastroenterology; 1998; 45(24):2282-94. PubMed ID: 9951911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 199.